论文部分内容阅读
Hepatocellular carcinoma (HCC) is an aggressive malignancy that arises in chronic liver disease. It is currently responsible for over 695,000 deaths inteationally every year and its incidence continues to rise as liver cirrhosis and its complications persist as major health problems worldwide (1,2). Liver transplantation is considered a potential cure for HCC because it removes both the tumor and diseased liver at risk of malignant transformation. Initially results from liver transplantation for HCC, however, were disappointing due to high post-operative mortality rates, recurrence rates of up to 80％, and poor long-term survival (3,4). It gradually became apparent that successful liver transplantation for HCC was dependent on careful selection of patients with limited disease (5).